Shubhnita Singh

Shubhnita Singh

Auto-generated profile, based on publicly available information

Shubhnita Singh

University of Pittsburgh

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2024 in Hypertension
Verified
Journal Article
Closed access
RCRafael M. Costa
Rafael M. Costa
DCDébora M. Cerqueira
Débora M. Cerqueira
ABAriane Bruder-Nascimento
Ariane Bruder-Nascimento
JAJuliano V. Alves
Juliano V. Alves
WAWanessa M.C. Awata
Wanessa M.C. Awata
TNThiago Bruder do Nascimento
Thiago Bruder do Nascimento
BACKGROUND: Aldosterone has been described to initiate cardiovascular diseases by triggering exacerbated sterile vascular inflammation. The functions of CCL5 (C-C motif chemokine ligand 5) and its receptor CCR5 (C-C motif chemokine receptor 5) are well known in infectious diseases, their contributions to aldosterone-induced vascular injury and hypertension remain unknown. METHODS: We analyzed the vascular profile, blood pressure, and renal damage in wild-type (CCR5 +/+ ) and CCR5 knockout (CCR5 −/− ) mice treated with aldosterone (600 µg/kg per day for 14 days) while receiving 1% saline to drink. Vascular function was analyzed in aorta and mesenteric arteries, blood pressure was measured by telemetry and renal injury and inflammation were analyzed via histology and flow cytometry. Endothelial cells were used to study the molecular signaling whereby CCL5 induces endothelial dysfunction. RESULTS: Aldosterone treatment resulted in exaggerated CCL5 circulating levels and vascular CCR5 expression in CCR5 +/+ mice accompanied by endothelial dysfunction, hypertension, and renal inflammation and damage. CCR5 −/− mice were protected from these aldosterone-induced effects. Mechanistically, we demonstrated that CCL5 increased NOX1 (NADPH oxidase 1) expression, reactive oxygen species formation, NFκB (nuclear factor kappa B) activation, and inflammation and reduced NO production in isolated endothelial cells. These effects were abolished by antagonizing CCR5 with Maraviroc. Finally, aorta incubated with CCL5 displayed severe endothelial dysfunction, which is prevented by blocking NOX1, NFκB, or CCR5. CONCLUSIONS: Our data demonstrate that CCL5/CCR5, through activation of NFκB and NOX1, is critically involved in aldosterone-induced vascular and renal damage and hypertension placing CCL5 and CCR5 as potential therapeutic targets for conditions characterized by aldosterone excess.

15 August 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
ABAriane Bruder‐Nascimento
Ariane Bruder‐Nascimento
WAWanessa M. C. Awata
Wanessa M. C. Awata
JAJuliano V. Alves
Juliano V. Alves
SSShubhnita Singh
Shubhnita Singh
RCRafael M. Costa
Rafael M. Costa
TNThiago Bruder do Nascimento
Thiago Bruder do Nascimento
Background: The mechanisms determining vascular tone are still not completely understood, even though it is a significant factor in blood pressure management. Many circulating proteins have a significant impact on controlling vascular tone. Progranulin displays anti‐inflammatory effects and has been extensively studied in neurodegenerative illnesses. We investigated whether progranulin sustains the vascular tone that helps regulate blood pressure. Methods and Results: We used male and female C57BL6/J wild type (progranulin +/+ ) and B6(Cg)‐Grn tm1.1Aidi /J (progranulin −/− ) to understand the impact of progranulin on vascular contractility and blood pressure. We found that progranulin −/− mice display elevated blood pressure followed by hypercontractility to noradrenaline in mesenteric arteries, which is restored by supplementing the mice with recombinant progranulin. In ex vivo experiments, recombinant progranulin attenuated the vascular contractility to noradrenaline in male and female progranulin +/+ arteries, which was blunted by blocking EphrinA2 or Sortilin1. To understand the mechanisms whereby progranulin evokes anticontractile effects, we inhibited endothelial factors. N(gamma)‐nitro‐L‐arginine methyl ester (nitric oxide synthase inhibitor) prevented the progranulin effects, whereas indomethacin (cyclooxygenase inhibitor) affected only the contractility in arteries incubated with vehicle, indicating that progranulin increases nitric oxide and decreases contractile prostanoids. Finally, recombinant progranulin induced endothelial nitric oxide synthase phosphorylation and nitric oxide production in isolated mesenteric endothelial cells. Conclusions: Circulating progranulin regulates vascular tone and blood pressure via EphrinA2 and Sortilin1 receptors and endothelial nitric oxide synthase activation. Collectively, our data suggest that deficiency in progranulin is a cardiovascular risk factor and that progranulin might be a new therapeutic avenue to treat high blood pressure.

9 November 2023 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
WAWanessa M.C. Awata
Wanessa M.C. Awata
JAJuliano V. Alves
Juliano V. Alves
RCRafael M. Costa
Rafael M. Costa
ABAriane Bruder-Nascimento
Ariane Bruder-Nascimento
SSShubhnita Singh
Shubhnita Singh
TNThiago Bruder do Nascimento
Thiago Bruder do Nascimento
Renin-angiotensin (Ang II)-aldosterone system (RAAS) is crucial for the cardiovascular risk associated with excessive ethanol consumption. Disturbs in mitochondria have been implicated in multiple cardiovascular diseases. However, if mitochondria dysfunction contributes to ethanol-induced vascular dysfunction is still unknown. We investigated whether ethanol leads to vascular dysfunction via RAAS activation, mitochondria dysfunction, and mitochondrial reactive oxygen species (mtROS). Male C57/BL6J or mt-keima mice (6-8-weeks old) were treated with ethanol (20% vol./vol.) for 12 weeks with or without Losartan (10 mg/kg/day). Ethanol induced aortic hypercontractility in an endothelium-dependent manner. PGC1α (a marker of biogenesis), Mfn2, (an essential protein for mitochondria fusion), as well as Pink-1 and Parkin (markers of mitophagy), were reduced in aortas from ethanol-treated mice. Disturb in mitophagy flux was further confirmed in arteries from mt-keima mice. Additionally, ethanol increased mtROS and reduced SOD2 expression. Strikingly, losartan prevented vascular hypercontractility, mitochondrial dysfunction, mtROS, and restored SOD2 expression. Both MnTMPyP (SOD2 mimetic) and CCCP (a mitochondrial uncoupler) reverted ethanol-induced vascular dysfunction. Moreover, L-NAME (NOS inhibitor) and EUK 134 (superoxide dismutase/catalase mimetic) did not affect vascular response in ethanol group, suggesting that ethanol reduces aortic nitric oxide (NO) and H2O2 bioavailability. These responses were prevented by losartan. AT1 receptor modulates ethanol-induced vascular hypercontractility by promoting mitochondrial dysfunction, mtROS, and reduction of NO and H2O2 bioavailability. Our findings shed a new light in our understanding of ethanol-induced vascular toxicity and open perspectives of new therapeutic approaches for patients with disorder associated with abusive ethanol drinking.

4 February 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
SSShubhnita Singh
Shubhnita Singh
ABAriane Bruder
Ariane Bruder
RCRafael Costa
Rafael Costa
JAJuliano V. Alves
Juliano V. Alves
SBSivakama Bharathi
Sivakama Bharathi
TNThiago Bruder do Nascimento
Thiago Bruder do Nascimento
Background: The complex interplay between vascular contractility and mitochondrial function is central to cardiovascular disease. The progranulin gene ( GRN ) encodes glycoprotein PGRN (progranulin), a ubiquitous molecule with known anti‐inflammatory property. However, the role of PGRN in cardiovascular disease remains undefined. In this study, we sought to dissect the significance of PGRN in the regulation vascular contractility and investigate the interface between PGRN and mitochondrial quality. Methods and Results: We used aortae from male and female C57BL6/J wild‐type (PGRN+/+) and B6(Cg)‐Grntm1.1Aidi/J (PGRN−/−) mice. Our results showed suppression of contractile activity in PGRN−/−, followed by reduced α‐smooth muscle actin expression. Mechanistically, PGRN deficiency suppressed mitochondrial respiration, induced mitochondrial fission, and disturbed autophagy process and redox signaling, while restoration of PGRN levels in aortae from PGRN−/− mice via lentivirus delivery ameliorated contractility and boosted mitochondria activity. In addition, in vivo treatment with mitochondrial fission inhibitor restored mitochondrial quality and vascular contractility, while vascular smooth muscle cells overexpressing PGRN displayed higher lysosome biogenesis, accelerated mitophagy flux, and mitochondrial respiration accompanied by vascular hypercontractility. Finally, angiotensin II failed to induce vascular contractility in PGRN−/−, suggesting a key role of PGRN to maintain the vascular tone. Conclusions: Our findings suggest that PGRN preserves the vascular contractility via regulating mitophagy flux, mitochondrial activity and dynamics, and redox signaling. Therefore, loss of PGRN function appears as a pivotal risk factor in cardiovascular disease.

1 June 2025 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
RCRafael Costa
Rafael Costa
ABAriane Bruder-Nascimento
Ariane Bruder-Nascimento
JAJuliano V. Alves
Juliano V. Alves
WAWanessa M. C. Awata
Wanessa M. C. Awata
SSShubhnita Singh
Shubhnita Singh
RTRita de Cássia Tostes
Rita de Cássia Tostes
Elevated aldosterone levels, as seen in primary hyperaldosteronism, obesity, and hypertension, impair autophagic flux in perivascular adipose tissue (PVAT), leading to increased inflammation and loss of anticontractile function. The Beclin-1-dependent autophagic pathway plays a key role in maintaining PVAT homeostasis and vascular tone. Disrupted autophagy contributes to oxidative stress and hypertension. Activating this pathway may offer a novel therapeutic strategy to mitigate aldosterone’s harmful vascular effects in hypertension by restoring PVAT function and vascular inflammation.

23 September 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
RCRafael Menezes Costa
Rafael Menezes Costa
DCDebora Malta Cerqueira
Debora Malta Cerqueira
ABAriane Bruder-Nascimento
Ariane Bruder-Nascimento
JAJuliano Vilela Alves
Juliano Vilela Alves
WAWanessa A.C. Awata
Wanessa A.C. Awata
TNThiago Bruder do Nascimento
Thiago Bruder do Nascimento
Background: Aldosterone, a mineralocorticoid steroid hormone, has been described to initiate cardiovascular diseases by triggering exacerbated sterile vascular inflammation. The functions of C-C Motif Chemokine Ligand 5 (CCL5) and its receptor, C-C Motif Chemokine Receptor 5 (CCR5), are well known in infectious diseases, but their roles in the genesis of aldosterone-induced vascular injury and hypertension are unknown. Methods: We analyzed the vascular profile, blood pressure, and renal damage in wild-type (CCR5 +/+ ) and CCR5 knockout (CCR5 −/− ) mice treated with aldosterone (600 µg/kg/day for 14 days) while receiving 1% saline to drink. Results: Here, we show that CCR5 plays a central role in aldosterone-induced vascular injury, hypertension, and renal damage. Long-term infusion of aldosterone in CCR5 +/+ mice resulted in exaggerated CCL5 circulating levels and vascular CCR5 expression. Aldosterone treatment also triggered vascular injury, characterized by endothelial dysfunction and inflammation, hypertension, and renal damage. Mice lacking CCR5 were protected from aldosterone-induced vascular damage, hypertension, and renal injury. Mechanistically, we demonstrated that CCL5 increased NADPH oxidase 1 (Nox1) expression, reactive oxygen species (ROS) formation, NFκB activation, and inflammation and reduced nitric oxide production in isolated endothelial cells. These effects were abolished by antagonizing CCR5 with Maraviroc. Finally, aortae incubated with CCL5 displayed severe endothelial dysfunction, which is prevented by blocking Nox1, NFκB, or with Maraviroc treatment. Conclusions: Our data demonstrate that CCL5/CCR5, through activation of NFkB and Nox1, is critically involved in aldosterone-induced vascular and renal damage and hypertension. Our data place CCL5 and CCR5 as potential targets for therapeutic interventions in conditions with aldosterone excess.